SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

Loading...

Patheon launches CMC consultancy in face of restructuring plans

By Natalie Morrison , 15-May-2012

Patheon has launched a new consulting service designed to give emerging biotechs and pharmas a boost in their drug development efforts.

The provision, named Certified Consulting will see a team of 12 industry veterans providing their CMC (chemistry, manufacturing and controls) know-how for mid to late stage developers.

The CDMO (contract development and manufacturing organisation) says it will “draw the road map” for companies making decisions to drive molecules from discovery to development and scale-up.

Speaking to Outsourcing-Pharma at Interphex, Geoff Glass, executive VP of global sales and marketing said: “CMC – part of turning that molecule into something you and I can absorb as humans – is becoming more and more challenging.

“The industry has churned out more of these BCS (biopharmaceutical classification system) class II and IV compounds recently, and those products by their very nature require more complex techniques.”

He said Patheon spoke to the bods in charge at said companies, where there was a synonymous cry for guidance to prevent “making the mistakes a small company without the right knowledge set might make.”

Turn and face the change

The news comes in the midst of a structural overhaul for the firm , which will see many of its contract manufacturing operations in Swindon, UK, axed.

And it seems the Certified Consulting program falls in line with its efforts to “refocus” its business efforts on core operational programs.

In a statement the firm said that through the cuts, it would: “focus capital investments on its core business, and accelerate operational excellence programs to increase efficiency, meet customer needs, and improve its cost structure.”

Under the plans, 91 workers within the plant – which produces cephalosporin antibiotics and other sterile products – stand to loose their jobs by the end of the year, with a total of 400 employees hanging in the balance over the next three years.

Patheon expects to take a hit of around $55 to $65 million in payouts and redundancy packages.

The firm declined to comment when in-PharmaTechnologist asked if we should expect more service offerings similar to the Certified Consulting program, and more closures of manufacturing facilities.

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co